<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Emery, Paul</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">The RADIATE Study</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2008-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">20-21</style></pages><abstract><style  face="normal" font="default" size="100%">Although anti-TNF therapies are established treatments for rheumatoid arthritis (RA), significant proportions of patients do not achieve an adequate response, or become refractory to them. This article presents data from the RADIATE study [NCT00106522], a randomized, double-blind study that investigated the efficacy and safety of treatment with tocilizumab plus methotrexate in patients with moderate to severe RA and a prior history of failed anti-TNF therapy.</style></abstract><number><style face="normal" font="default" size="100%">5</style></number><volume><style face="normal" font="default" size="100%">8</style></volume></record></records></xml>